Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial

Show other versions (1)

Background: Patients with hepatocellular carcinoma (HCC) and Child–Pugh B liver cirrhosis have poor prognosis and are underrepresented in clinical trials. The CELESTIAL trial, in which cabozantinib improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with HCC...

Full description

Bibliographic Details
Main Authors: Abou-Alfa, G.K (Author), Cheng, A.-L (Author), El-Khoueiry, A.B (Author), Kelley, R.K (Author), Meyer, T. (Author), Milwee, S. (Author), Rimassa, L. (Author), Sen, S. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
adult
Adult
anilide
Anilides
antineoplastic agent
Antineoplastic Agents
cabozantinib
Cabozantinib
Carcinoma, Hepatocellular
Child–Pugh B
controlled study
Hepatocellular carcinoma
human
Humans
liver cell carcinoma
liver cirrhosis
Liver Cirrhosis
Liver Neoplasms
liver tumor
pathology
Prospective Studies
prospective study
pyridine derivative
Pyridines
randomized controlled trial
Retrospective Studies
retrospective study
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items